Research programme: anti-cancer immunotherapies - ImmunoMet Therapeutics

Drug Profile

Research programme: anti-cancer immunotherapies - ImmunoMet Therapeutics

Alternative Names: IM-156; IM-176; IM-184; IM-188

Latest Information Update: 23 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmunoMet Therapeutics
  • Class Antineoplastics; Biguanides; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Mar 2017 ImmunoMet Therapeutics plans a phase I trial of IM 156 for Glioblastoma in the second quarter of 2017
  • 07 Mar 2017 Preclinical trials in Cancer in USA, before March 2017
  • 25 Oct 2016 ImmunoMet Therapeutics has patents pending for IM 156 in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top